Evidence map›Paper›PMID 40741330›Full record

ArticleFrontiers in cell and developmental biology2025

Network analysis of master regulators associated with invasive phenotypes in multiple myeloma.

Feng Qian, Yubo Wang, Qinghong Shi

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Feng QianDepartment of Anesthesiology, China-Japan Union Hospital of Jilin University, Changchun, China.
Yubo WangDepartment of Clinical Laboratory, China-Japan Union Hospital of Jilin University, Changchun, China.
Qinghong ShiDepartment of Clinical Laboratory, China-Japan Union Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To elucidate the role of transcriptional regulators (TRs) associated with invasiveness in multiple myeloma (MM), we conducted a systematic network analysis to identify key master regulators (MRs) that govern MM invasiveness. We employed a consensus clustering method based on a 24-gene signature to classify MM patients into high invasiveness (INV-H) and low invasiveness (INV-L) groups. Subsequently, we identified TRs specific to the INV-H and INV-L phenotypes as MRs using a network-based approach, and we validated the MR activities that correlated with the INV-H phenotype across multiple independent datasets. We evaluated the effect of MRs on patient outcomes in relation to the prognosis of MM. By utilizing siRNA to disrupt ERG expression in U266 and RPMI8226 cell lines, we evaluated the effects of the master regulator ERG on the proliferation, apoptosis, invasion, and migration of myeloma cell lines, and we confirmed the expression of ERG in patients with extramedullary MM. We assessed invasiveness using a 24-gene signature, categorizing patients into INV-H and INV-L groups. Our network identified MRs linked to MM invasiveness and revealed enriched signaling pathways. High ERG expression correlated with poor prognosis. ERG silencing reduced cell invasiveness, migration, and apoptosis, while promoting proliferation. Elevated ERG was found in extramedullary MM, and potential drug candidates, including Idarubicin, were identified for treatment. This study provides a comprehensive analysis of master regulators in EMM, contributing to targeted therapeutic strategies. We identified ERG as a marker for extramedullary invasion in MM, suggesting it as a potential therapeutic target for future interventions.

Indexed as

EMMergidarubicininvasivenessmaster regulators

Identifiers

PMID40741330
PMCPMC12307296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.